Metrics as of 10/13/2026, 06:35 PM (Berlin time), refresh in progress.
Vor Biopharma Stock
Vor Biopharma Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jean-Paul Kress
- Employees
- 76
- Market cap
- $1 B
- IPO
- 05/02/2021
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute…
Vor Biopharma stock: price history
1D
-3.7%
1W
+4.1%
1M
-14.5%
6M
+20.1%
YTD
+45.7%
1Y
-41.0%
2Y
+42.2%
5Y
-93.3%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~5% stronger price swings than usual
Ask the agents about Vor Biopharma
Analyst assessment of Vor Biopharma
PRICE TARGET LOW
US$27.00
CONSENSUS
US$29.00
MEDIAN
US$29.00
PRICE TARGET HIGH
US$31.00
0
STRONG BUY
10
BUY
3
HOLD
0
SELL
0
STRONG SELL
13
TOTAL · Buy
As of: 12/08/2026
Vor Biopharma stock metrics
P/E
-0.06
P/B
-5.17
EV/EBITDA
1.44
RETURN ON EQUITY
31.4%
NET MARGIN
0.0%
DEBT/EQUITY
-0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
520.4%
FLOAT SHARES
281,980,052
AVG. DAILY VOLUME (30D)
1,164,546
Insider transactions (SEC)
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Vor Biopharma stock
What does Vor Biopharma do?
Vor Biopharma Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jean-Paul Kress, the company employs around 76 people.
The IPO was on 05/02/2021; the stock trades on NASDAQ under the ticker VOR.
What do analysts say about Vor Biopharma stock?
13 analysts rate the stock, the consensus is Buy (as of 12/08/2026).
The average price target is US$29.00, ranging from US$27.00 to US$31.00, with a median of US$29.00.
This is an external assessment, not a statement by Market Jury.
When does Vor Biopharma report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Vor Biopharma pay a dividend?
No, Vor Biopharma currently does not pay a dividend.
Which stocks are comparable to Vor Biopharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vor Biopharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vor Biopharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.